Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 18.55% is 16% above its 5-year average of 15.96%, near the high end of its 5-year range (8.20%–22.68%).
3.88% above its 12-month average of 17.86%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2026 (2026-06-30): 19.29%.
EBITDA MARGIN
18.55%
EBITDA MARGIN AVG TTM
17.86%
EBITDA MARGIN AVG 3Y
17.77%
EBITDA MARGIN AVG 5Y
15.96%
EBITDA MARGIN AVG 10Y
16.21%
EBITDA MARGIN AVG 15Y
11.90%
EBITDA MARGIN AVG 20Y
10.31%
CURRENT VS TTM AVG
+3.88%
CURRENT VS 3Y AVG
+4.42%
CURRENT VS 5Y AVG
+16.24%
CURRENT VS 10Y AVG
+14.42%
CURRENT VS 15Y AVG
+55.86%
CURRENT VS 20Y AVG
+79.91%
Market Cap
$208.37M
EBITDA Margin
-611.99%
TTM Avg
-293.95%
3Y Avg
-196.05%
5Y Avg
-196.05%
Market Cap
$211.33M
EBITDA Margin
43.70%
TTM Avg
-4.00%
3Y Avg
-127.66%
5Y Avg
-437.76%
Market Cap
$206.05M
EBITDA Margin
-646.93%
TTM Avg
-391.16%
3Y Avg
-256.59%
5Y Avg
-321.84%
Market Cap
$211.79M
EBITDA Margin
-847.24%
TTM Avg
-1408.92%
3Y Avg
-1408.92%
5Y Avg
-1408.92%
Market Cap
$203.92M
EBITDA Margin
-2994.14%
TTM Avg
-1551.99%
3Y Avg
-854.53%
5Y Avg
-625.57%
Market Cap
$214.41M
EBITDA Margin
-533986.11%
TTM Avg
-544963.54%
3Y Avg
-316138.98%
5Y Avg
-211520.31%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pro-Dex, Inc. (PDEX) | $208.71M | 18.55% | 17.86% | 17.77% | 15.96% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $208.37M | -611.99% | -293.95% | -196.05% | -196.05% |
| Electra Therapeutics Inc. (ETRA)vs › | $206.82M | N/A | N/A | N/A | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $206.19M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $211.33M | 43.70% | -4.00% | -127.66% | -437.76% |
| Alector, Inc. (ALEC)vs › | $206.05M | -646.93% | -391.16% | -256.59% | -321.84% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $211.79M | -847.24% | -1408.92% | -1408.92% | -1408.92% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $203.92M | -2994.14% | -1551.99% | -854.53% | -625.57% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $214.41M | -533986.11% | -544963.54% | -316138.98% | -211520.31% |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | 12.17% | 10.71% | -1.62% | -12.53% |
Gross Margin
31.4%
EBITDA Margin
18.6%
Operating Margin
16.8%
Net Margin
17.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 19.29% |
| 2026-03-31 | 17.33% |
| 2025-12-31 | 19.14% |
| 2025-09-30 | 18.46% |
| 2025-06-30 | 15.07% |
| 2025-03-31 | 22.68% |
| 2024-12-31 | 17.89% |
| 2024-09-30 | 22.26% |
| 2024-06-30 | 17.68% |
| 2024-03-31 | 17.48% |
| 2023-12-31 | 8.44% |
| 2023-09-30 | 17.70% |
| 2023-06-30 | 17.61% |
| 2023-03-31 | 17.38% |
| 2022-12-31 | 11.76% |
| 2022-09-30 | 10.31% |
| 2022-06-30 | 10.80% |
| 2022-03-31 | 12.96% |
| 2021-12-31 | 17.56% |
| 2021-09-30 | 15.10% |
| 2021-06-30 | 8.20% |
| 2021-03-31 | 17.49% |
| 2020-12-31 | 8.36% |
| 2020-09-30 | 19.78% |
| 2020-06-30 | 21.12% |
| 2020-03-31 | 21.72% |
| 2019-12-31 | 22.76% |
| 2019-09-30 | 22.50% |
| 2019-06-30 | 18.71% |
| 2019-03-31 | 14.75% |
| 2018-12-31 | 20.32% |
| 2018-09-30 | 26.26% |
| 2018-06-30 | 9.91% |
| 2018-03-31 | 14.45% |
| 2017-12-31 | 9.06% |
| 2017-09-30 | 19.66% |
| 2017-06-30 | 17.17% |
| 2017-03-31 | 22.53% |
| 2016-12-31 | 8.81% |
| 2016-09-30 | 7.98% |
| 2016-06-30 | 6.26% |
| 2016-03-31 | 3.69% |
| 2015-12-31 | 10.31% |
| 2015-09-30 | 1.22% |
| 2015-06-30 | 6.14% |
| 2015-03-31 | -6.40% |
| 2014-12-31 | -9.35% |
| 2014-09-30 | -2.39% |
| 2014-06-30 | 3.52% |
| 2014-03-31 | -13.44% |
| 2013-12-31 | -8.52% |
| 2013-09-30 | 5.99% |
| 2013-06-30 | -20.32% |
| 2013-03-31 | -20.46% |
| 2012-12-31 | -7.75% |
| 2012-09-30 | 2.86% |
| 2012-06-30 | -17.70% |
| 2012-03-31 | -11.41% |
| 2011-12-31 | -2.28% |
| 2011-09-30 | 10.38% |
| 2011-06-30 | 17.66% |
| 2011-03-31 | 17.02% |
| 2010-12-31 | 12.04% |
| 2010-09-30 | 9.90% |
| 2010-06-30 | -66.91% |
| 2010-03-31 | 9.48% |
| 2009-12-31 | 5.58% |
| 2009-09-30 | 7.49% |
| 2009-06-30 | 7.79% |
| 2009-03-31 | -31.99% |
| 2008-12-31 | 5.50% |
| 2008-09-30 | 1.17% |
| 2008-06-30 | -11.10% |
| 2008-03-31 | 4.32% |
| 2007-12-31 | 10.19% |
| 2007-09-30 | 10.68% |
| 2007-06-30 | 8.70% |
| 2007-03-31 | 8.01% |
| 2006-12-31 | -3.84% |
| 2006-09-30 | 10.34% |
| 2006-06-30 | 5.40% |
| 2006-03-31 | 2.87% |
| 2005-12-31 | 15.47% |
| 2005-09-30 | 13.63% |
| 2005-06-30 | 25.69% |
| 2005-03-31 | 10.68% |
| 2004-12-31 | 13.48% |
| 2004-09-30 | 23.47% |
| 2004-06-30 | 21.69% |
| 2004-03-31 | 14.54% |
| 2003-12-31 | 13.39% |
| 2003-09-30 | 12.05% |
| 2003-06-30 | 9.06% |
| 2003-03-31 | 6.14% |
| 2002-12-31 | 2.81% |
| 2002-09-30 | 4.09% |
